论文部分内容阅读
目的:探讨中药复方益髓理血饮对二甲基苯蒽(DMBA)诱导的骨髓增生异常综合征(MDS)模型大鼠骨髓病态造血的改善作用及其机制。方法:将清洁级雄性SD大鼠分为正常对照组、模型组、复方皂矾丸阳性组及益髓理血饮低、高剂量组,每组12只。用DMBA诱导建立大鼠MDS模型,于造模第14天开始分组给药,连续30 d。给药后第31天处死各组大鼠,检测各组大鼠骨髓增生程度、病态造血,血清IL-3、TNF-α含量,股骨CD34表达及原始细胞所占比。结果:与正常对照组比较,模型组骨髓增生程度和骨髓病态造血明显,各给药组骨髓增生和病态造血明显改善;模型组血清IL-3含量显著降低(P<0.01),TNF-α含量显著升高(P<0.01),治疗后各给药组IL-3含量显著升高(P<0.05),TNF-α含量降低(P<0.05);模型组股骨CD34及髓CD45阳性表达(P<0.01),治疗后股骨CD34表达和原始细胞比例均显著降低(P<0.05)。以上改善均以高剂量组最为明显。结论:益髓理血饮治疗骨髓增生异常综合征能改善骨髓增生程度和病态造血,升高血清IL-3含量,降低血清TNF-α含量,减少股骨CD34阳性表达,降低股骨原始细胞比例。
Objective: To investigate the effect and mechanism of Yiyao Liquor Drink, a traditional Chinese medicine compound, on myelopoiesis in bone marrow of rats with myelodysplastic syndrome (MDS) induced by dimethylbenzyl anthracene (DMBA). Methods: Male SD rats of clean grade were divided into normal control group, model group, Zaofan Pills positive group and Yixue Li Xueyin low and high dose groups, 12 rats in each group. The rat model of MDS was induced by DMBA, and began to be divided into groups on the 14th day after administration for 30 days. On the 31st day after administration, the rats in each group were sacrificed and the degree of bone marrow hyperplasia, pathological hematopoiesis, serum IL-3 and TNF-α levels, femoral CD34 expression and the proportion of blasts were determined. Results: Compared with the normal control group, the degree of myeloproliferation and myelopathic hematopoiesis in the model group were significantly increased, and the bone marrow hyperplasia and pathological hematopoiesis were significantly improved in each treatment group. The levels of IL-3 in the model group were significantly decreased (P <0.01) (P <0.01). After treatment, the levels of IL-3 in each group were significantly increased (P <0.05) and the contents of TNF-α were decreased (P <0.05) <0.01). After treatment, the expression of CD34 and the percentage of blasts in the femur decreased significantly (P <0.05). These improvements are the most obvious high-dose group. Conclusion: The treatment of myelodysplastic syndrome with myelodysplastic syndrome can improve the degree of bone marrow hyperplasia and pathological hematopoiesis, increase the level of serum IL-3, decrease the level of serum TNF-α, decrease the expression of CD34 in femur and the proportion of femur blasts.